Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in:

22-11-2024 | Type 1 Diabetes | REVIEW

Glucose Control During Labour and Delivery in Type 1 Diabetes – An Update on Current Evidence

Authors: Lene Ringholm, Julie Carstens Søholm, Berit Woetmann Pedersen, Tine Dalsgaard Clausen, Peter Damm, Elisabeth Reinhardt Mathiesen

Published in: Current Diabetes Reports | Issue 1/2025

Login to get access

Abstract

Purpose of Review

To provide an update on diabetes management during labour and delivery in women with type 1 diabetes with focus on appropriate insulin administration, carbohydrate supply and use of diabetes technology to support safe delivery and neonatal well-being.

Recent Findings

During active labour and elective cesarean section capillary blood glucose monitoring or continuous glucose monitoring at least hourly is recommended. Infusion with isotonic (5%) glucose can be given with adjustable infusion rate to address maternal carbohydrate requirements and to prevent maternal hypoglycemia. Subcutaneous insulin administration with multiple injections or insulin pump therapy is considered at least as safe and efficient as intravenous administration to obtain tight glycemic targets. Automated insulin delivery via insulin pump can be continued during labour and delivery.

Summary

Diabetes management during labour and delivery involves intensive glucose monitoring, adequate insulin administration and carbohydrate administration to support safe delivery and neonatal well-being.
Literature
1.
Dashora U, Levy N, Dhatariya K, Willer N, Castro E, Murphy HR. Managing hyperglycaemia during antenatal steroid administration, labour and birth in pregnant women with diabetes - an updated guideline from the Joint British Diabetes Society for Inpatient Care. Diabet Med. 2022;39(2). https://​pubmed.​ncbi.​nlm.​nih.​gov/​34811800/​
2.
Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and diabetes: a report of aworkgroup of the American diabetes association and the endocrine society. Diabetes Care. 2013;36(5):1384–95.CrossRefPubMedPubMedCentral
3.
Keller MF, Vestgaard M, Damm P, Mathiesen ER, Ringholm L. Treatment with the long-acting insulin analog degludec during pregnancy in women with type 1 diabetes: an observational study of 22 cases. Diabetes Res Clin Pract. 2019;152:58–64.CrossRefPubMed
4.
5.
6.
Benhalima K, Beunen K, Siegelaar SE, Painter R, Murphy HR, Feig DS, et al. Management of type 1 diabetes in pregnancy: update on lifestyle, pharmacological treatment, and novel technologies for achieving glycaemic targets. Lancet Diabetes Endocrinol. 2023;11(7):490–508.CrossRefPubMed
7.
Colstrup M, Mathiesen ER, Damm P, Jensen DM, Ringholm L. Pregnancy in women with type 1 diabetes: have the goals of St. Vincent declaration been met concerning foetal and neonatal complications? J Maternal-Fetal Neonatal Med. 2013;26(17):1682–6.CrossRef
8.
Ekbom P, Damm P, Feldt-Rasmussen B, Feldt-Rasmussen U, Jensen DM, Mathiesen ER. Elevated third-trimester haemoglobin A1c predicts preterm delivery in type 1 diabetes. J Diabetes Complications. 2008;22(5):297–302.CrossRefPubMed
9.
Glinianaia SV, Tennant PWG, Bilous RW, Rankin J, Bell R. HbA1c and birthweight in women with pre-conception type 1 and type 2 diabetes: a population-based cohort study. Diabetologia. 2012;55(12):3193–203.CrossRefPubMed
10.
Murphy HR, Howgate C, O’Keefe J, Myers J, Morgan M, Coleman MA, et al. Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study. Lancet Diabetes Endocrinol. 2021;9(3):153–64.CrossRefPubMed
11.
Nørgaard SK, Vestgaard MJ, Jørgensen IL, Ásbjörnsdóttir B, Ringholm L, McIntyre HD, et al. Diastolic blood pressure is a potentially modifiable risk factor for preeclampsia in women with pre-existing diabetes. Diabetes Res Clin Pract. 2018;138:229–37.CrossRefPubMed
12.
13.
Mackin ST, Nelson SM, Wild SH, Colhoun HM, Wood R, Lindsay RS. Factors associated with stillbirth in women with diabetes. Diabetologia. 2019;1(10):1938–47.CrossRef
14.
Mackin ST, Nelson SM, Kerssens JJ, Wood R, Wild S, Colhoun HM. Diabetes and pregnancy: national trends over a 15 year period. Diabetologia. 2018;61(5):1081–8.PubMedPubMedCentral
15.
Gortazar L, Goday A, Flores-Le Roux JA, Sarsanedas E, Payà A, Mañé L et al. Trends in prevalence of pre-existing diabetes and perinatal outcomes: a large, population-based study in Catalonia, Spain, 2006–2015. BMJ Open Diabetes Res Care. 2020;8(1):e001254.
16.
17.
Søholm JC, Do NC, Vestgaard M, Ásbjörnsdóttir B, Nørgaard SK, Pedersen BW, et al. Falling insulin requirement in pregnant women with diabetes delivering Preterm: prevalence, predictors, and consequences. J Clin Endocrinol Metab. 2022;107(6):E2237–44.CrossRefPubMed
18.
Feig DS, Berger H, Donovan L, Godbout A, Kader T, Keely E, et al. Diabetes and pregnancy. Can J Diabetes. 2018;42:S255–82.CrossRefPubMed
19.
Søholm JC, Vestgaard M, Ásbjörnsdóttir B, Do NC, Pedersen BW, Storgaard L, et al. Potentially modifiable risk factors of preterm delivery in women with type 1 and type 2 diabetes. Diabetologia. 2021;64(9):1939–48.CrossRefPubMed
20.
Do NC, Vestgaard M, Ásbjörnsdóttir B, Nørgaard SK, Andersen LLT, Jensen DM et al. Unchanged Prevalence of Preeclampsia After Implementation of Prophylactic Aspirin for All Pregnant Women With Preexisting Diabetes: A Prospective Cohort Study. Diabetes Care. 2021;44(10):2252–9. https://​pubmed.​ncbi.​nlm.​nih.​gov/​34400481/​
21.
Secher AL, Ringholm L, Andersen HU, Damm P, Mathiesen ER. The effect of real-time continuous glucose monitoring in pregnant women with diabetes A randomized controlled trial. Diabetes Care. 2013;36(7):1877–83.CrossRefPubMedPubMedCentral
22.
23.
24.
25.
Yoeli-Ullman R, Maayan-Metzger A, Zemet R, Dori Dayan N, Mazaki-Tovi S, Cohen O et al. The association between novel glucose indices in parturients with type 1 diabetes mellitus and clinically significant neonatal hypoglycemia. Gynecol Endocrinol. 2020;36(7):615–9. https://​pubmed.​ncbi.​nlm.​nih.​gov/​31825267/​
26.
27.
Fresa R, Visalli N, Di Blasi V, Cavallaro V, Ansaldi E, Trifoglio O et al. Experiences of continuous subcutaneous insulin infusion in pregnant women with type 1 diabetes during delivery from four Italian centers: a retrospective observational study. Diabetes Technol Ther. 2013;15(4):328–34. https://​pubmed.​ncbi.​nlm.​nih.​gov/​23537417/​
28.
Drever E, Tomlinson G, Bai AD, Feig DS. Insulin pump use compared with intravenous insulin during labour and delivery: the INSPIRED observational cohort study. Diabet Med. 2016;33(9):1253–9.CrossRefPubMed
29.
30.
31.
Feldberg D, Dicker D, Samuel N, Peleg D, Karp M, Goldman JA. Intrapartum management of insulin-dependent diabetes mellitus (IDDM) gestants. A comparative study of constant intravenous insulin infusion and continuous subcutaneous insulin infusion pump (CSIIP). Acta Obstet Gynecol Scand. 1988;67(4):333-8. https://​pubmed.​ncbi.​nlm.​nih.​gov/​3051881/​
32.
Light IJ, Keenan WJ, Sutherland JM. Maternal intravenous glucose administration as a cause of hypoglycemia in the infant of the diabetic mother. Am J Obstet Gynecol. 1972;113(3):345–50.CrossRefPubMed
33.
34.
Yamamoto JM, Donovan LE, Mohammad K, Wood SL. Severe neonatal hypoglycaemia and intrapartum glycaemic control in pregnancies complicated by type 1, type 2 and gestational diabetes. Diabet Med. 2020;37(1):138–46.CrossRefPubMed
35.
Yamamoto JM, Corcoy R, Donovan LE, Stewart ZA, Tomlinson G, Beardsall K, et al. Maternal glycaemic control and risk of neonatal hypoglycaemia in type 1 diabetes pregnancy: a secondary analysis of the CONCEPTT trial. Diabet Med. 2019;36(8):1046–53.CrossRefPubMed
36.
37.
Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593–603. https://​pubmed.​ncbi.​nlm.​nih.​gov/​31177185/​
38.
Beunen K, Gillard P, Van Wilder N, Ballaux D, Vanhaverbeke G, Taes Y et al. Advanced Hybrid Closed-Loop Therapy Compared With Standard Insulin Therapy Intrapartum and Early Postpartum in Women With Type 1 Diabetes: A Secondary Observational Analysis From the CRISTAL Randomized Controlled Trial. Diabetes Care. 2024; 47(11):2002–2011. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​39331059
39.
Cordua S, Secher AL, Ringholm L, Damm P, Mathiesen ER. Real-time continuous glucose monitoring during labour and delivery in women with type 1 diabetes - observations from a randomized controlled trial. Diabet Med. 2013;30(11):1374–81.CrossRefPubMed
40.
41.
Citro F, Bianchi C, Aragona M, Belcari T, Battini L, Marchetti P et al. Accuracy of intermittently scanned continuous glucose monitoring during caesarean delivery in pregnant women with insulin-treated diabetes. Diabetes Res Clin Pract. 2024;210:111611. https://​pubmed.​ncbi.​nlm.​nih.​gov/​38479448/​
42.
Ringholm L, Nørgaard SK, Rytter A, Damm P, Mathiesen ER. Dietary advice to support glycaemic control and Weight Management in women with type 1 diabetes during pregnancy and breastfeeding. Nutrients. 2022;14(22):1–16.CrossRef
43.
Avari P, O’Regan A, Preechasuk L, Oliver N, Agha-Jaffar R. Adjustment of maternal variable rate insulin infusions using real-time continuous glucose monitoring in pregnant women with type 1. Diabetes Diabetes Technol Ther. 2023;25(4):293–7.CrossRefPubMed
44.
Nørgaard SK, Mathiesen ER, Nørgaard K, Ringholm L. Comparison of Glycemic Metrics measured simultaneously by intermittently scanned continuous glucose monitoring and real-time continuous glucose monitoring in pregnant women with type 1 diabetes. Diabetes Technol Ther. 2021;23(10):665–72.CrossRefPubMed
45.
Rosenberg VA, Eglinton GS, Rauch ER, Skupski DW. Intrapartum maternal glycemic control in women with insulin requiring diabetes: a randomized clinical trial of rotating fluids versus insulin drip. Am J Obstet Gynecol. 2006;195(4):1095–9.CrossRefPubMed
46.
47.
Wilkie GL, Delpapa E, Leftwich HK. Intrapartum continuous subcutaneous insulin infusion vs intravenous insulin infusion among pregnant individuals with type 1 diabetes mellitus: a randomized controlled trial. Am J Obstet Gynecol. 2023;229(6):680.e1-680.e8.CrossRef
48.
Benhalima K, Jendle J, Beunen K, Ringholm L. Automated insulin delivery for pregnant women with type 1 diabetes: where do we stand? J Diabetes Sci Technol. 2024;18(6):1334–45.CrossRefPubMed
49.
Lee TTM, Collett C, Bergford S, Hartnell S, Scott EM, Lindsay RS et al. Automated insulin delivery in women with pregnancy complicated by type 1 diabetes. N Engl J Med. 2023;389(17).
50.
Albert L, Romero A, Capel I, Cano A, Subías D, Casamitjana L, et al. Off-label use of an automated insulin delivery system in pregnant women with type 1 diabetes. Diabetes Res Clin Pract. 2023;202:110800.CrossRefPubMed
51.
Munda A, Kovacic C, Pongrac Barlovic D. Carbohydrate intake and closed-Loop insulin delivery system during two subsequent pregnancies in type 1 diabetes. Metabolites. 2022;12(11).
52.
Wang XS, Dunlop AD, McKeen JA, Feig DS, Donovan LE. Real-world use of Control-IQ™ technology automated insulin delivery in pregnancy: a case series with qualitative interviews. Diabet Med. 2023;40(6).
53.
Quirós C, Herrera Arranz MT, Amigó J, Wägner AM, Beato-Vibora PI, Azriel-Mira S, et al. Real-world evidence of off-label use of commercially automated insulin Delivery systems compared to multiple daily insulin injections in pregnancies complicated by type 1 diabetes. Diabetes Technol Ther. 2024;26(8):596–606.PubMed
54.
Benhalima K, Beunen K, Van Wilder N, Ballaux D, Vanhaverbeke G, Taes Y et al. Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2024; 12(6):390–403 https://​pubmed.​ncbi.​nlm.​nih.​gov/​38697182/​
55.
Nørgaard SK, Nørgaard K, Roskjær AB, Mathiesen ER, Ringholm L. Insulin pump settings during breastfeeding in women with type 1 diabetes. Diabetes Technol Ther. 2020;22(4):314–20.CrossRefPubMed
56.
Ringholm L, Roskjær AB, Engberg S, Andersen HU, Secher AL, Damm P, et al. Breastfeeding at night is rarely followed by hypoglycaemia in women with type 1 diabetes using carbohydrate counting and flexible insulin therapy. Diabetologia. 2019;62(3):387–98.CrossRefPubMed
57.
ElSayed NA, Aleppo G, Bannuru RR, Bruemmer D, Collins BS, Ekhlaspour L, et al. 15. Management of diabetes in pregnancy: standards of Care in diabetes – 2024. Diabetes Care. 2024;47(Supplement1):S282–94.
58.
59.
60.
61.
Heller SR. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: A joint position statement of the American diabetes association and the European association for the study of diabetes. Diabetes Care. 2017;40(1).
62.
63.
Achong N, McIntyre HD, Callaway L, Duncan EL. Glycaemic behaviour during breastfeeding in women with type 1 diabetes. Diabet Med. 2016;33(7):947–55.CrossRefPubMed
64.
Janney CA, Zhang D, Sowers M. Lactation and weight retention. Am J Clin Nutr. 1997;66(5).
65.
Bergmann KE, Bergmann RL, Von Kries R, Böhm O, Richter R, Dudenhausen JW et al. Early determinants of childhood overweight and adiposity in a birth cohort study: role of breast-feeding. Int J Obes. 2003;27(2).
66.
Feig DS, Lipscombe LL, Tomlinson G, Blumer I. Breastfeeding predicts the risk of childhood obesity in a multi-ethnic cohort of women with diabetes. J Maternal-Fetal Neonatal Med. 2011;24(3).
67.
Hummel S, Pflüger M, Kreichauf S, Hummel M, Ziegler AG. Predictors of overweight during childhood in offspring of parents with type 1 diabetes. Diabetes Care. 2009;32(5).
68.
Weyermann M, Rothenbacher D, Brenner H. Duration of breastfeeding and risk of overweight in childhood: a prospective birth cohort study from Germany. Int J Obes. 2006;30(8).
69.
Borch-Johnsen K, Mandrup-Poulsen T, Zachau-Christiansen B, Joner G, Christy M, Kastrup K et al. Relation between breast-feeding and incidence rates of insulin-dependent diabetes mellitus. A Hypothesis. Vol. 324, The Lancet. 1984.
70.
Kimpimäki T, Erkkola M, Korhonen S, Kupila A, Virtanen SM, Ilonen J et al. Short-term exclusive breastfeeding predisposes young children with increased genetic risk of type I diabetes to progressive beta-cell autoimmunity. Diabetologia. 2001;44(1).
71.
Sadauskaite-Kuehne VV, Ludvigsson J, Padaiga Ž, Jašinskiene E, Samuelsson U. Longer breastfeeding is an independent protective factor against development of type 1 diabetes mellitus in childhood. Diabetes Metab Res Rev. 2004;20(2).
72.
Owen CG, Martin RM, Whincup PH, Smith GD, Cook DG. Does breastfeeding influence risk of type 2 diabetes in later life? A quantitative analysis of published evidence. Am J Clin Nutr. 2006;84(5).
73.
74.
Kakoulidis I, Ilias I, Linardi A, Michou A, Milionis C, Lekkou A et al. Insulin requirements during lactation in women with diabetes mellitus type 1 in comparison with pre-pregnancy levels: A 10-year retrospective study. Health Care Women Int. 2022;43(1–3):309–12. https://​pubmed.​ncbi.​nlm.​nih.​gov/​34586960/​
75.
Skajaa GØ, Kampmann U, Ovesen PG, Fuglsang J. Breastfeeding and insulin requirements in women with type 1 diabetes mellitus in the first year postpartum. Acta Diabetol. 2023;60(7):899–906.CrossRefPubMed
76.
Nørgaard SK, Søholm JC, Mathiesen ER, Nørgaard K, Clausen TD, Holmager P, et al. Faster-acting insulin aspart versus insulin aspart in the treatment of type 1 or type 2 diabetes during pregnancy and post-delivery (CopenFast): an open-label, single-centre, randomised controlled trial. Lancet Diabetes Endocrinol. 2023;11(11):811–21.CrossRefPubMed
77.
Achong N, Duncan EL, McIntyre HD, Callaway L. Peripartum management of glycemia in women with type 1 diabetes. Diabetes Care. 2014;37(2):364–71.CrossRefPubMed
78.
Riviello C, Mello G, Jovanovic LG. Breastfeeding and the basal insulin requirement in type 1 diabetic women. Endocr Pract. 2009;15:187–93.
79.
Dietary Reference Intakes for Energy. Carbohydrate, Fiber, Fat, fatty acids, cholesterol, protein, and amino acids (macronutrients). Dietary reference intakes for Energy, Carbohydrate, Fiber, Fat, fatty acids, cholesterol, protein, and amino acids (macronutrients). National Academies; 2005. pp. 290–2. Available online:. http://​www.​nap.​edu/​read/​10490/​chapter/​6.
80.
McLaughlin C, McCance DR. Diabetic management in labor, delivery and post delivery. In: McCance DR, Maresh M, Sacks DA, editors. A practical manual of diabetes in pregnancy. 1st ed. Wiley-Blackwell; 2008. pp. 211–9.
81.
82.
Nørgaard SK, Nichum VL, Barfred C, Juul HM, Secher AL, Ringholm L et al. Use of the smartphone application pregnant with diabetes. Dan Med J. 2017; 64(11).
83.
84.
Metadata
Title
Glucose Control During Labour and Delivery in Type 1 Diabetes – An Update on Current Evidence
Authors
Lene Ringholm
Julie Carstens Søholm
Berit Woetmann Pedersen
Tine Dalsgaard Clausen
Peter Damm
Elisabeth Reinhardt Mathiesen
Publication date
22-11-2024

Other articles of this Issue 1/2025

The Influence of Racial Discrimination as a Chronic Stressor on Type 2 Diabetes Risk and Self-Management Behaviors among Black Adults: A Scoping Review

Beyond the Scale: Exploring the Endocannabinoid System’s Impact on Obesity

Diabetes, OCD, schizophrenia, and bipolar disorder

Normal Weight Central Obesity and its Impact on Type 2 Diabetes Mellitus

Parental Psychosocial Variables and Glycemic Control in T1D Pediatric Age: A Systematic Review

Inpatient Hypoglycemic Rate Reduction Through the Implementation of Prescriber Targeted Decision Support Tools

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits